We provide you with 20 years of free, institutional-grade data for GERN stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of GERN. Explore the full financial landscape of GERN stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Spiegel Robert J. | Grant, award...etc | 5,540 | $1.41 | 2025-07-01 | |
| LAWLIS V BRYAN | Open Market Purchase | 13,300 | $1.18 | 2025-05-13 | |
| Spiegel Robert J. | Grant, award...etc | 13,264 | $4.54 | 2025-04-02 | |
| Samuels Scott Alan | Open Market Purchase | 15,000 | $1.61 | 2025-03-03 | |
| Ziegler James | Open Market Purchase | 100,000 | $1.6 | 2025-03-03 | |
| SCARLETT JOHN A | Open Market Purchase | 12,500 | $1.76 | 2025-03-03 | |
| Spiegel Robert J. | Grant, award...etc | -2,206 | 2025-01-02 | ||
| Spiegel Robert J. | Grant, award...etc | -1,767 | 2024-10-01 | ||
| GRETHLEIN ANDREW J | Sale | -674,348 | $4.56 | $3,073,004 | 2024-07-10 |
| GRETHLEIN ANDREW J | Derivatives Exercise | 674,348 | 2024-07-10 | ||
| Spiegel Robert J. | Grant, award...etc | -4,378 | 2024-06-28 | ||
| Kapur Anil | Sale | -421,875 | $4.64 | $1,959,609 | 2024-06-12 |
| Kapur Anil | Derivatives Exercise | 421,875 | 2024-06-12 | ||
| Feller Faye | Sale | -287,900 | $4.63 | $1,334,129 | 2024-06-12 |
| Feller Faye | Derivatives Exercise | 287,900 | 2024-06-12 | ||
| SCARLETT JOHN A | Sale | -600,000 | $4 | $2,400,000 | 2024-06-05 |
| SCARLETT JOHN A | Derivatives Exercise | 600,000 | 2024-06-05 | ||
| LAWLIS V BRYAN | Sale | -35,000 | $3.75 | $131,250 | 2024-05-17 |
| LAWLIS V BRYAN | Derivatives Exercise | 35,000 | 2024-05-17 | ||
| Spiegel Robert J. | Grant, award...etc | 3,406 | 2024-01-03 | ||
| Molineaux Susan | Grant, award...etc | 6,220 | 2024-01-03 | ||
| Aggarwal Gaurav | Grant, award...etc | 1,970 | 2024-01-03 | ||
| Molineaux Susan | Grant, award...etc | 6,191 | 2023-10-02 | ||
| Spiegel Robert J. | Grant, award...etc | 3,390 | 2023-10-02 | ||
| O'Farrell Elizabeth G. | Open Market Purchase | 6,579 | $2.28 | 2023-08-24 | |
| O'Farrell Elizabeth G. | Open Market Purchase | 6,607 | $2.28 | 2023-08-24 | |
| Molineaux Susan | Grant, award...etc | 4,088 | 2023-06-30 | ||
| Spiegel Robert J. | Grant, award...etc | 2,239 | 2023-06-30 | ||
| Kapur Anil | Grant, award...etc | 7,567 | $2.04 | 2023-06-30 | |
| LAWLIS V BRYAN | Sale | -35,000 | $3 | $105,000 | 2023-05-11 |
| LAWLIS V BRYAN | Derivatives Exercise | 35,000 | 2023-05-11 | ||
| Molineaux Susan | Sale | -35,000 | $2.48 | $86,800 | 2023-05-01 |
| Molineaux Susan | Derivatives Exercise | 35,000 | 2023-05-01 | ||
| Molineaux Susan | Grant, award...etc | 6,048 | 2023-04-03 | ||
| Spiegel Robert J. | Grant, award...etc | 3,312 | 2023-04-03 | ||
| Bloom Olivia Kyusuk | Sale | -400,000 | $3.08 | $1,232,000 | 2023-02-10 |
| Bloom Olivia Kyusuk | Derivatives Exercise | 400,000 | 2023-02-10 | ||
| GRETHLEIN ANDREW J | Sale | -384,719 | $3.03 | $1,165,699 | 2023-02-10 |
| GRETHLEIN ANDREW J | Derivatives Exercise | 150,000 | 2023-02-10 | ||
| SCARLETT JOHN A | Sale | -1,340,000 | $3.08 | $4,127,200 | 2023-02-10 |
| SCARLETT JOHN A | Derivatives Exercise | 1,340,000 | 2023-02-10 | ||
| EASTHAM KARIN | Derivatives Exercise | 35,000 | 2023-01-17 | ||
| Spiegel Robert J. | Grant, award...etc | 2,970 | 2023-01-03 | ||
| Kapur Anil | Grant, award...etc | 6,021 | $1.11 | 2023-01-03 | |
| Spiegel Robert J. | Grant, award...etc | 3,071 | 2022-10-03 | ||
| GRETHLEIN ANDREW J | Derivatives Exercise | 234,719 | 2022-09-14 | ||
| Kapur Anil | Grant, award...etc | 13,062 | $1.11 | 2022-07-01 | |
| Spiegel Robert J. | Grant, award...etc | 4,637 | 2022-07-01 |
The information provided in this report about GERN stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Geron Corporation(NASDAQ:GERN) 
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation ...
Website: http://www.geron.com
Founded: 1990
Full Time Employees: 45
Sector: Healthcare
Industry: Biotechnology